In a preclinical model with HER2-positive breast cancer patient-derived xenografts, TAK-228 sensitised tumours to trastuzumab, so that the combination of both drugs strongly suppressed tumour growth [54]. The gene discussed is ERBB2; the disease is breast carcinoma.